Physician profile

Tara Mescher

Family · Claremont, NH

NPI 1689002495

$199.14

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$185.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $66.02 2024 Ozempic, Rybelsus
Abbvie INC. $38.51 2024
Glaxosmithkline, LLC. $28.06 2024 Nucala, Trelegy Ellipta
Lilly USA, LLC $21.62 2024 Zepbound, Jardiance
Astrazeneca Pharmaceuticals LP $16.77 2024 Airsupra
Otsuka America Pharmaceutical, INC. $14.40 2024 Rexulti
Biohaven Pharmaceutical Holding Company LTD. $13.76 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tara Mescher

$199.14

in general payments reported 2019-2025

Years
2022-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/10895576/tara-mescher

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.